743 related articles for article (PubMed ID: 30873822)
21. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
22. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
[TBL] [Abstract][Full Text] [Related]
23. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
24. NLRX1 regulates TNF-α-induced mitochondria-lysosomal crosstalk to maintain the invasive and metastatic potential of breast cancer cells.
Singh K; Roy M; Prajapati P; Lipatova A; Sripada L; Gohel D; Singh A; Mane M; Godbole MM; Chumakov PM; Singh R
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1460-1476. PubMed ID: 30802640
[TBL] [Abstract][Full Text] [Related]
25. FOXP2 Promotes Tumor Proliferation and Metastasis by Targeting GRP78 in Triple-negative Breast Cancer.
Wu J; Liu P; Tang H; Shuang Z; Qiu Q; Zhang L; Song C; Liu L; Xie X; Xiao X
Curr Cancer Drug Targets; 2018; 18(4):382-389. PubMed ID: 29484998
[TBL] [Abstract][Full Text] [Related]
26. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
27. Biologic roles of estrogen receptor-β and insulin-like growth factor-2 in triple-negative breast cancer.
Hamilton N; Márquez-Garbán D; Mah V; Fernando G; Elshimali Y; Garbán H; Elashoff D; Vadgama J; Goodglick L; Pietras R
Biomed Res Int; 2015; 2015():925703. PubMed ID: 25874233
[TBL] [Abstract][Full Text] [Related]
28. Drivers and suppressors of triple-negative breast cancer.
Wu W; Warner M; Wang L; He WW; Zhao R; Guan X; Botero C; Huang B; Ion C; Coombes C; Gustafsson JA
Proc Natl Acad Sci U S A; 2021 Aug; 118(33):. PubMed ID: 34389675
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
30. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
31. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.
He R; Liu P; Xie X; Zhou Y; Liao Q; Xiong W; Li X; Li G; Zeng Z; Tang H
J Exp Clin Cancer Res; 2017 Oct; 36(1):145. PubMed ID: 29037220
[TBL] [Abstract][Full Text] [Related]
32. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine.
Hu J; Zhang Y; Jiang X; Zhang H; Gao Z; Li Y; Fu R; Li L; Li J; Cui H; Gao N
J Exp Clin Cancer Res; 2019 May; 38(1):225. PubMed ID: 31138329
[TBL] [Abstract][Full Text] [Related]
33. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
Ma R; Karthik GM; Lövrot J; Haglund F; Rosin G; Katchy A; Zhang X; Viberg L; Frisell J; Williams C; Linder S; Fredriksson I; Hartman J
J Natl Cancer Inst; 2017 Mar; 109(3):1-14. PubMed ID: 28376210
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.
Xu F; Xu K; Fan L; Li X; Liu Y; Yang F; Zhu C; Guan X
Chin Med J (Engl); 2024 Feb; 137(3):338-349. PubMed ID: 38105538
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
36. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
37. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
38. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
Salahuddin A; Ghanem H; Omran GA; Helmy MW
Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
